Holen Sie sich die Stockscreener-App
184.38
1.86%
-3.50
Handel nachbörslich:
184.38
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen Buyout Bet On Felzartamab: A Hidden Blockbuster In The Making? - Smartkarma
The Goldman Sachs Group Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $21.83 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Should Biogen’s (BIIB) Full Global Control of Felzartamab Require Action From Investors? - simplywall.st
BofA raises Biogen stock price target to $200 on base business - Investing.com
Goldman Sachs Adjusts Price Target on Biogen to $238 From $231, Maintains Buy Rating - marketscreener.com
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise? - TradingView
Wolfe Research Has Bearish Forecast for Biogen Q2 Earnings - MarketBeat
Postpartum Depression Market is projected to Hit USD 93.6 - openPR.com
Biogen secures FDA nod for higher dose of SMA drug Spinraza - MSN
Analysts estimate Biogen Inc. (BIIB) to report a decline in earnings: What to look out for - MSN
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Biogen Gains China Felzartamab Rights As Valuation Gap Draws Attention - simplywall.st
JPMorgan Adjusts Price Target on Biogen to $185 From $175, Maintains Neutral Rating - marketscreener.com
Jim Cramer Says “I Got to Reopen the File on Biogen” - Insider Monkey
BIIB (Biogen Inc.) exceeds Q4 2025 earnings forecasts, shares tick higher on steady year over year revenue growth.Joint Venture - Cổng thông tin điện tử tỉnh Lào Cai
Earnings preview: Biogen Inc. (BIIB) Q1 earnings expected to decline - MSN
Biogen Loses Multiple Sclerosis Treatment Patent On Appeal - Law360
Biogen strengthens global pipeline with $100m TJ biopharma partnership - BioXconomy
BIOGEN LT-Debt-to-Total-Asset: 0.22 | Fairly Valued - GuruFocus
BIIB (Biogen) Other Income (Minority Interest) : $0 Mil (TTM As of Dec. 2025) - GuruFocus
BIIB (Biogen) Fixed Maturity Investment - GuruFocus
Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027 - Proactive financial news
Biogen Stock Analysis: Recent Gains Mask Long-Term Financial WeaknessNews and Statistics - IndexBox
BIOGEN Tax Provision: $-264 Mil | Fairly Valued - GuruFocus
BIOGEN Debt-to-Revenue: 0.72 | Fairly Valued - GuruFocus
BIIB (Biogen) DeferredTaxAndRevenue : $0 Mil (As of Dec. 2025) - GuruFocus
BIOGEN Total Equity: $18,257 Mil | Fairly Valued - GuruFocus
UBS upgrades Biogen, sees up to 50% upside on pipeline catalysts - Investing.com Canada
Biogen's Q1 Earnings Call to Focus on BIIB080 Data and Apellis Deal, Oppenheimer Says - marketscreener.com
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade? - 24/7 Wall St.
BIIB Upgraded by UBS -- Price Target Raised to $225 - GuruFocus
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline - Yahoo Finance
FY2026 Earnings Estimate for Biogen Issued By HSBC - MarketBeat
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Biogen, Cava Group, GitLab, Halliburton, Qualcomm, Seagate, Toast, and More - Yahoo Finance
Biogen (BIIB) Projected to Post Earnings on Wednesday - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Sells 11,837 Shares of Biogen Inc. $BIIB - MarketBeat
UBS Upgrades Biogen to Buy From Neutral, Adjusts Price Target to $225 From $185 - marketscreener.com
Analyst recommendations: Albemarle, Biogen, Qualcomm, Twilio, Lyondellbasell… - marketscreener.com
TJ Biopharma enters into agreement with Biogen for Felzartamab assets in Greater China Region - BioSpectrum Asia
UBS upgrades Biogen stock rating on pipeline catalysts, raises target to $225 - Investing.com
UBS upgrades Biogen (BIIB) - MSN
Biogen Inc. (BIIB)Secures Exclusive Global Felzartamab Rights via Greater China Licensing Deal, Shares RallyViral Trade Signals - UBND thành phố Hải Phòng
Biogen Inc. (BIIB) – Strategic Portfolio Review Signals Near-Term Earnings HeadwindsDividend Yield - Xã Vĩnh Công
Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen - Yahoo Finance
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Inc. Secures Global Rights To Felzartamab Through Greater China Deal With TJ Biopharma - BioPharma APAC
Biogen amasses full felzartamab rights with $850M TJ deal - BioWorld News
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up - TradingView
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead - Yahoo Finance
Amyloid Setback: Future Possibilities For The Treatment Of Alzheimer's Disease - Seeking Alpha
Biogen gets worldwide development and commercialization rights to felzartamab - The Pharma Letter
HSBC Predicts Biogen's Q1 Earnings (NASDAQ:BIIB) - MarketBeat
Mirae Asset Global Investments Co. Ltd. Decreases Position in Biogen Inc. $BIIB - MarketBeat
Lobbying Update: $1,460,000 of BIOGEN lobbying was just disclosed - Quiver Quantitative
Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance
Biogen Inc (BIIB) Shares Surge 3.4% -- What GF Score of 72 Tells Investors - GuruFocus
Biogen (BIIB) Stock: Is It Forming a Reversal (Technical Strength) 2026-04-20Hot Community Stocks - Xã Châu Thành
Biogen Inc. stock (US09062X1037): Is its neurology focus strong enough to drive new upside? - AD HOC NEWS
Biogen earnings preview: What to expect - MSN
Biogen (BIIB) Secures Exclusive Rights to Felzartamab in Greater China - GuruFocus
BIIB Upgraded by Wells Fargo -- Price Target Raised to $250 - GuruFocus
Biogen Earnings Preview: What to Expect - Barchart.com
Biogen to buy China rights to immune disease drug for up to $850M - Seeking Alpha
Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act? - 24/7 Wall St.
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma - Reuters
1.24%
2.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):